Examination of Immunosuppression Adjustment Impact on Kidney Function in Liver Transplant

Exclusion Criteria

• •<!-- -->
• •1. \< 18 years old
• •2. Autoimmune liver disease, Primary Sclerosing Cholangitis, Primary Biliary Cirrhosis
• •3. Dialysis greater than 45 days
• •4. Receiving ATG, IVIG therapy, or sirolimus/everolimus around time of transplant or sirolimus/everolimus after transplant
• •5. Unable to take oral medications
• •6. Participating in another clinical research study involving the evaluation of another investigational drug or device
• •7. Documented allergy to basiliximab, TAC, MMF or any macrolide antibiotic.
• •8. Presence of thrombosis of any major hepatic arteries
• •9. Complex/high risk arterial reconstruction at any time (graft vessel patency by Doppler ultrasound confirmed and documented).
• •10. Patients who are recipients of multiple solid organ transplants, (e.g., multivisceral or combined liver-kidney transplants), or have previously received an organ or tissue transplanted, or who received an ABO incompatible transplant.
• •11. Patients who have severe hypercholesterolemia (\>215 mg/dL; \>5.5 mmol/L) or hypertriglyceridemia (\>265 mg/dL; \>3.0 mmol/L) at Baseline.
• •12. Patients who have severe thrombocytopenia or neutropenia (platelet count \>20 and MLCs\>1000)
• •13. Patients who have any surgical or medical condition, which in the opinion of the investigator, might significantly alter the absorption, distribution, metabolism and excretion of study drugs
• •14. Patients with a known hypersensitivity to the drugs used on study or their class, or to any of the excipients.
• •15. Patients with clinically significant systemic infection
• •16. Pregnant or nursing (lactating) female patients, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive βHCG laboratory test (\>9 mIU/mL) at Baseline.